Uterine sarcoma is a relatively rare and highly malignant tumor of the female genital tract that arises from the myometrium or intra-myometrium connective tissue. It is more common in perimenopausal women, with a high prevalence at age 50. The most common symptom is irregular vaginal bleeding with more or less volume. If the tumor is infected with necrosis, there may be a large amount of purulent discharge with foul smell. Patients may feel that the abdominal mass is rapidly increasing, and if it presses on the rectum and bladder, symptoms such as frequent urination, urinary retention and difficulty in defecation may occur. When sarcoma is suspected, segmental curettage is an effective adjunctive diagnostic method. It should also be combined with ultrasound and CT to help diagnose, but of course the final diagnosis needs to be based on pathological results. Uterine sarcoma can easily metastasize to the lungs, so lung X-ray should be routinely performed. The principle of treatment is mainly surgery. Depending on the early or late stage of the disease, chemotherapy or radiotherapy will be administered after surgery. For sarcoma with fibroid malignancy, the malignancy is generally low and the prognosis is good, but other types of uterine sarcoma have high malignancy and poor prognosis, and the 5-year survival rate of uterine sarcoma is only 20-30%. For women with uterine fibroids that do not require surgical treatment, they should be checked regularly for fibroids. If they grow too fast in a short period of time or increase in size instead of shrinking after menopause, they should be alerted to malignant changes.